Piramal Pharma FY26 results: revenue ₹8,869.08 crore

FY26 result announcement and why it matters

Piramal Pharma Limited has announced its financial results for the year ended March 31, 2026, reporting audited numbers on both standalone and consolidated bases. The disclosures come alongside key corporate governance updates, including leadership re-appointments and a change in the company’s compliance leadership. For investors tracking the Pharma and CDMO space, the split between standalone profitability and consolidated loss is a key takeaway from the filing. The company also referenced specific operational and exceptional items that influenced consolidated performance during the year. Separately, regulatory and board process updates were also communicated through stock exchange intimation around the FY26 board meeting.

FY2026 revenue snapshot: standalone vs consolidated

For FY2026, Piramal Pharma reported standalone revenue of ₹4,782.01 crore. On a consolidated basis, revenue stood at ₹8,869.08 crore for the same period. The large gap between standalone and consolidated revenue reflects the scale of operations captured at the group level compared with the standalone entity. The filing focuses attention on the consolidated picture because it includes the broader operating footprint and related items that can materially affect bottom-line outcomes.

Standalone profit after tax improves year-on-year

On a standalone basis, Piramal Pharma reported profit after tax (PAT) of ₹700.01 crore for the year ended March 31, 2026. This compared with ₹691.40 crore in the previous year, indicating a modest improvement year-on-year. The standalone numbers, by definition, do not capture all subsidiaries and consolidation adjustments. Still, the increase in standalone PAT provides a reference point for underlying profitability at the entity level. The contrast with the consolidated loss highlights that group-level items and consolidation impacts were significant in FY2026.

Consolidated net loss and the impairment charge

For FY2026, Piramal Pharma reported a consolidated net loss after tax of ₹325.94 crore. The company attributed the outcome to various operational and exceptional items during the year. A key disclosed factor was an impairment charge of ₹175.82 crore recognised in FY2026. The impairment is a material item in the context of the reported consolidated loss and is specifically called out in the financial performance overview provided. Beyond the impairment, the company indicated that multiple operational and exceptional items contributed to the final consolidated result.

Board and leadership updates: chairperson and executive director

Alongside the financial results, Piramal Pharma confirmed key leadership re-appointments. The company re-appointed Ms. Nandini Piramal as Chairperson and Executive Director. Such re-appointments are typically relevant to investors because they signal continuity in board leadership and oversight, especially around periods when operating performance includes exceptional items. The disclosures also included decisions related to independent directors, strengthening the governance aspects of the update.

Independent directors re-appointed for a second term

The board approved the re-appointment of Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson for a second term of five consecutive years. The effective date for these re-appointments was disclosed as March 30, 2027. Independent director tenures and renewal timelines are closely tracked as part of board composition and governance compliance. By specifying the start date and term length, the company has provided clarity on the forward governance calendar.

New company secretary and compliance officer from April 29, 2026

Piramal Pharma also announced the appointment of Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer. The appointment is effective April 29, 2026. The company secretary and compliance officer role is central to stock exchange compliance, disclosure processes, and coordination with the board and regulators. The effective date places the change immediately after the late-April board meeting cycle related to FY26 audited results.

Board meeting timeline and trading window closure

Through stock exchange communication, Piramal Pharma informed BSE that a meeting of the Board of Directors was scheduled on April 28, 2026. The stated agenda included considering and approving the audited financial results, standalone and consolidated, for the quarter and financial year ended March 31, 2026. The company also disclosed that the trading window closure began on April 1, 2026 and would remain closed until April 30, 2026, inclusive. These disclosures are standard for companies during sensitive financial reporting windows, particularly around audited results and board approvals.

Recent quarterly context: Q2 and Q3 FY26 disclosures

Earlier disclosures in FY26 provide context around operating trends referenced by the company in prior updates. For Q3 FY26, consolidated revenue was ₹2,140 crore, compared with ₹2,204 crore in Q3 FY25, a year-on-year change of (3)%. For 9M FY26, consolidated revenue was ₹6,117 crore compared with ₹6,397 crore in 9M FY25, a change of (4)%. Q3 FY26 EBITDA was ₹239 crore with an 11% margin, compared with ₹350 crore and a 16% margin in Q3 FY25; 9M FY26 EBITDA was ₹628 crore with a 10% margin versus ₹977 crore and a 15% margin in 9M FY25.

For Q2 FY26, revenue from operations was ₹2,044 crore compared with ₹2,242 crore in Q2 FY25, a change of (9)%. Q2 FY26 EBITDA was ₹224 crore compared with ₹403 crore in Q2 FY25, a change of (44)%, with an EBITDA margin of 11%. The company also disclosed a Q2 FY26 PAT of ₹-99 crore compared with ₹23 crore during Q2 FY25. In a separate H1 FY26 update, the company reported net debt at the end of H1 FY26 reduced by ₹228 crore (vs FY25) to ₹3,971 crore, supported by working capital control and capex investments, while maintaining net debt to EBITDA ratio below 3x.

Key disclosed data at a glance

What investors typically track after audited disclosures

The FY26 disclosures highlight a clear divergence between standalone profitability and consolidated loss, with the impairment charge explicitly identified as a meaningful item in the year. Investors typically focus on whether such exceptional items are one-off and how they relate to underlying operating trends already visible in quarterly disclosures. Governance updates, including key leadership re-appointments and compliance officer changes, also matter because they set the framework for oversight and disclosure quality. Any further details on operational and exceptional items would usually be evaluated alongside segment performance and cash flow movements, but only the impairment amount is explicitly provided in the current information.

Conclusion

Piramal Pharma’s FY2026 audited disclosures show standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore, with standalone PAT improving to ₹700.01 crore while the group reported a consolidated net loss of ₹325.94 crore, including an impairment charge of ₹175.82 crore. The company also confirmed board and management updates, including Ms. Nandini Piramal’s re-appointment and the appointment of Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026. The board meeting scheduled for April 28, 2026 and the trading window closure through April 30, 2026 complete the immediate compliance timeline around the audited results.